ACAllison Mercedes Caban-Holt

Allison Mercedes Caban-Holt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Allison Mercedes Caban-Holt has a total of 136 co-authors. Here are the top co-authors by number of shared publications:

  • Goldie Smith Byrd

    Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA

    4 shared publications
  • Margaret Pericak-Vance

    John P. Hussman Institute for Human Genomic and the Dr John T. Macdonald Foundation Department of Human Genetics, University of Miami Miller School of Medicine, Miami, FL, USA

    3 shared publications
  • Brian W. Kunkle

    John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA

    2 shared publications
  • Christiane Reitz

    Affiliations Gertrude H. Sergievsky Center, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Department of Neurology, Columbia University, New York, New York, United States of America, Department of Epidemiology, Columbia University, New York, New York, United States of America

    2 shared publications
  • Colmar Figueroa-Moseley

    Southwest Oncology Group, Seattle, WA

    2 shared publications
  • Dana C. Crawford

    Affiliation Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America

    2 shared publications

Latest Publications

  • Recruiting and retaining persons with suspected Alzheimer's disease and related dementias for genetic studies in selected African countries: Lived realities of researchers

    by Olufisayo Elugbadebo, Temitope Farombi, Oyedunni Arulogun, Michelle Nichols, Mayowa Ogunronbi, Cynthia Olawuyi, Adelina Claudia Simbine, Amour Mkubila, Osimhiarherhuo Adeleye, Dorcas Olujobi, et al.

    Background: Genomic research in dementia in Africa is of utmost importance based on recent reports from studies on African-Americans that the African ancestral gene is associated with a lower risk effect for developing AD. However, dementia-related genetic studies are still evolving in sub-Saharan Africa, with unique challenges influencing participant recruitment. Objective: This study sought to identify key challenges of recruitment and retention how they were mitigated in the READD-ADSP Africa and ‘Origins of AD in African ancestry’ genetic studies. Methods: A qualitative narrative research design using in-depth interviews explored the challenges of recruiting participants and how these were managed by the nineteen stakeholders involved in the recruitment process from nine African countries participating in the African Dementia Consortium. An inductive thematic analysis was applied to code and analyze the data systematically. Results: Nineteen stakeholders from nine African countries, participating in READD-ADSP and ‘Origins’ studies were interviewed. Similar challenges were observed across most African countries, including the non-existing national dementia registry. Other challenges include language diversity, myths around blood collection, family dynamics, stigma, logistics, unmet expectations concerning incentives, fewer older controls and data privacy. Leveraging previous research programs, existing community engagement activities and client-doctor relationships were strategies used in addressing these challenges. Conclusions: There are some unique challenges with recruiting and retaining participants in genetic studies in Africa. Strengthening community engagement and advocacy for genomic research, alongside a well-populated dementia registry in the African Dementia Consortium, could overcome these challenges and improve participant recruitment in genetic studies.


  • Open Access

    Alzheimer disease is (sometimes) highly heritable: Drivers of variation in heritability estimates for binary traits, a systematic review

    by Shiying Liu, William S. Bush, Rufus Olusola Akinyemi, Goldie S. Byrd, Allison Mercedes Caban-Holt, Farid Rajabli, Christiane Reitz, Brian W. Kunkle, Guiseppe Tosto, Jeffery M. Vance, et al.

    Estimating heritability has been fundamental in understanding the genetic contributions to complex disorders like late-onset Alzheimer’s disease (LOAD) and provides a rationale for identifying genetic factors associated with disease susceptibility. While numerous studies have established substantial genetic contribution for LOAD, the interpretation of heritability estimates remains challenging. These challenges are further complicated by the binary nature of LOAD status, where estimation and interpretation require additional considerations. Through a systematic review, we identified LOAD heritability estimates from 6 twin studies and 17 genome-wide association studies, all conducted in populations of European ancestry. We demonstrate that these heritability estimates for LOAD vary considerably. The variation reflects not only differences in study design and methodological approaches but also the underlying study population characteristics. Our findings indicate that commonly cited heritability estimates, often treated as universal values, should be interpreted within specific population contexts and methodological frameworks.


  • Open Access

    Alzheimer disease is (sometimes) highly heritable: Drivers of variation in heritability estimates for binary traits, a systematic review

    by Shiying Liu, William S. Bush, Rufus Olusola Akinyemi, Goldie S. Byrd, Allison Mercedes Caban-Holt, Farid Rajabli, Christiane Reitz, Brian W. Kunkle, Giuseppe Tosto, Jeffery M. Vance, et al.

    Estimating heritability has been fundamental in understanding the genetic contributions to complex disorders like late-onset Alzheimer’s disease (LOAD), and provides a rationale for identifying genetic factors associated with disease susceptibility. While numerous studies have established substantial genetic contribution for LOAD, the interpretation of heritability estimates remains challenging. These challenges are further complicated by the binary nature of LOAD status, where estimation and interpretation require additional considerations. Through a systematic review, we identified LOAD heritability estimates from 6 twin studies and 17 genome-wide association studies, all conducted in populations of European ancestry. We demonstrate that these heritability estimates for LOAD vary considerably. The variation reflects not only differences in study design and methodological approaches but also the underlying study population characteristics. Our findings indicate that commonly cited heritability estimates, often treated as universal values, should be interpreted within specific population contexts and methodological frameworks.


  • Open Access

    Maya Angelou Center for Health Equity Caregiver College: a culturally‐relevant training for African American Alzheimer’s disease caregivers

    by Allison M Caban‐Holt, Takiyah D. Starks, Shawnta' Lloyd, Anita Ford, Sole' McCall, Samuela B. Eale, Lori Fuller, Goldie S. Byrd

    Background: African American (AA) caregivers of patients with Alzheimer’s disease (AD) and related disorders can play a critical role in maintaining patient health. The Maya Angelou Center for Health Equity at Wake Forest University School of Medicine Caregiver College (MC2) aims to (1) improve informal caregivers’ knowledge of AD and related disorders, (2) enhance the quality of life for AD patients and caregiver’s by providing awareness of and access to resources that can help reduce caregiver burden, (3) provide strategies to effectively manage patient symptoms associated with AD, and (4) fill gaps in culturally relevant health education and awareness on AD, brain health, and dementia caregiving skills for AAs.Method: The 40‐hour inaugural session of MC2 was conducted in‐person in October 2022. Educational sessions were facilitated by experts in various fields including AD, social work, nursing, aging, nutrition, and pharmacy. Topics covered over the course of the educational week included: Alzheimer’s Disease Overview, Health Disparities in AAs, Risk Factors for AD, End of Life Planning, and Caregiver Health. The 21‐item Dementia Knowledge Assessment Tool (DKAT), version 2 (Toye, et al. 2013) was used to track changes in AD knowledge and awareness. A DKAT pre‐test was administered before the educational sessions began on Day 1, and a post‐test assessment was administered at the end of the last educational session on Day 5.Result: Attendees (N = 21) are African American (100%), primarily female (90.48%), with an average age of 66.8 years (range 42‐82 years, 1 missing value). DKAT assessments from the week‐long educational training, showed an 8% increase in knowledge about AD in this sample of dementia caregivers based on a 5.7 percentage point increase on the DKAT from an average of 71.4% correct pre‐training to an average of 77.1% correct post‐training.Conclusion: Findings suggest that community‐based educational training is a useful strategy for improving AD knowledge and resource awareness for AA informal caregivers. Results will be used to expand this training to include community members who will be engaged through presentations by attendees of the MC2.

  • Open Access

    Perceptions of Brain donation and Medical Research Among African American Individuals: Implications for Recruitment and Retention into Alzheimer’s Research

    by Takiyah D. Starks, Allison M Caban‐Holt, Michael L. Cuccaro, Tayla Ford, Shawnta' Lloyd, Larry D. Adams, Johnathan L Haines, Christiane Reitz, Jeffery M. Vance, Margaret A. Pericak‐Vance, et al.

    Background: African Americans (AAs) are twice as likely to have Alzheimer’s disease (AD) as their White counterparts; yet, this population is largely missing from brain donation research. According to the National Alzheimer’s Coordinating Center, merely 2% of brain donations are obtained from AAs. Medical mistrust among AAs has been well‐documented as a barrier to medical research participation. The purpose of this study was to expand our understanding of AA perceptions of medical research and brain donation.Method: Using validated survey items, a 35‐item cross‐sectional survey was developed to understand attitudes and beliefs about medical research and brain donation among AAs. Surveys were administered via REDCap (Research Electronic Data Capture) and paper in Florida, New York, North Carolina and Ohio, United States from November 2021 to September 2022. Descriptive analysis of data on research participation and trust in medical research was conducted using SAS® software version 9.4.Result: A total of 227 AAs participated in this study with about three‐quarters of participants being female. Approximately 90% of AAs reported being born in the US, and nearly half of the sample reported receiving some college education or higher. Only 10.6% of participants reported being very likely to donate their brain to research after death. Despite the low percentage of AAs willing to donate their brain to research, 77.1% had a positive view of medical research and 72.7% trusted researchers in general. In fact, participants perceived that it is “very important” to participate in medical research to help future generations (78.4%), to learn more about AD (66.5%), and receive medical information (56.8%).Conclusion: Most AAs in this study reported strong trust in medical research and researchers. Medical mistrust may not be a significant barrier to participation in brain donation or AD research for AAs in this sample. Improved health literacy in AD research and brain donation procedures may facilitate engagement of AAs to participate in such research. Findings from this study will be used to inform the development of a culturally relevant health literacy program, with a focus on brain donation and AD research, to enhance opportunities for recruitment and retention of AAs.


  • Open Access

    49 Examining Associations Between Intelligence and Adaptive Functioning in Adults with Down Syndrome at Risk for Alzheimer's Disease

    by Sheliza Ali, Jordan Harp, Allison M. Caban-Holt, Brandon Dennis, Elizabeth Head, Jennifer Wells, Frederick Schmitt

    Objective:Individuals with Down syndrome (DS) experience intellectual disability, such that measures of cognitive and adaptive functioning are near the normative floor upon evaluation. Individuals with DS are also at increased risk for Alzheimer's disease (AD) beginning around age 40; and test performances and adaptive ratings at the normative floor make it difficult to detect change in cognition and functioning. This study first assessed the range of raw intelligence scores and raw adaptive functioning of individuals with DS at the normative floor. Next, we assessed whether those raw intelligence scores were predictive of raw adaptive functioning scores, and by association, whether they may be meaningful when assessing change in individuals with a lower baseline of cognitive functioning.Participants and Methods:Participants were selected from a cohort of 117 adults with DS in a longitudinal study examining AD risk. Participants (n=96; M=40.9 years-old, SD=10.67; 57.3% female) were selected if they had both a completed measure of IQ (Kaufmann Brief Intelligence Test; KBIT2) and informant ratings of adaptive functioning (Vineland Adaptive Behavior Scales; VABS-II). Multiple regression was conducted predicting VABS-II total raw score using K-BIT2 total raw score, while controlling for age.Results:A slight majority (57.3%) of the sample had a standardized IQ score of 40 with the majority (95.7%) having a standardized score at or below 60. Additionally, 85.3% of the sample had a standard VABS-II score at or below 60. Within the normative floor for the KBIT2 (IQ=40), there was a normal distribution and substantial range of both KBIT2 raw scores (M = 31.19, SD = 13.19, range: 2 to 41) and VABS-II raw scores (M = 406.33, SD = 84.91, range: 198 to 569). Using the full sample, age significantly predicted raw VABS-II scores (ß = -.283, p = .008). When KBIT2 raw scores were included in the model, age was no longer an independently significant predictor. KBIT2 raw scores significantly predicted raw VABS-II scores (ß = .689, p < .001). Age alone accounted for 8.0% of variance in VABS-II raw scores and KBIT2 raw scores accounted for 43.8% additional variance in VABS-II raw scores. This relationship was maintained when the sample was reduced to individuals at the normative floor (n = 51) where KBIT2 raw scores accounted for 23.7% of the variance in raw VABS-II scores (ß = .549, p < .001).Conclusions:The results indicate that meaningful variability exists among raw intelligence test performances that may be masked by scores at the normative floor. Further, the variability in raw intelligence scores is associated with variability in adaptive functioning, such that lower intelligence scores are associated with lower ratings of adaptive functioning. Considering this relationship would be masked by a reduction of range due to norming, these findings indicate that raw test performances and adaptive functioning ratings may have value when monitoring change in adults with DS at risk for AD.

  • Diversity, equity, and inclusion (DEI) champions: Lessons learned and implications for future programming to support cancer clinical trials.

    by Colmar Figueroa-Moseley, Lucy Gansauer, Jessica Dreger McDermott, Manuel Ricardo Espinoza Gutarra, Gayathri Nagaraj, Patricia A. Robinson, Rick Bangs, Allison Caban-Holt

  • Leadership knowledge and beliefs regarding diversity, equity, and inclusion at SWOG Cancer Research Network.

    by Manuel Ricardo Espinoza Gutarra, Colmar Figueroa-Moseley, Lucy Gansauer, Gayathri Nagaraj, Jessica Dreger McDermott, Rick Bangs, Allison Caban-Holt, Patricia A. Robinson

    E13599 Background: Diversity, Equity, and Inclusion (DEI) is recognized as fundamental in the development of generalizable clinical trials. Both ASCO and the FDA have released statements regarding the importance of representativeness in clinical trials. A paucity of research exists regarding the knowledge and beliefs of the people who lead the development of trials within the NCTN. Methods: An electronic survey on knowledge and beliefs regarding DEI was administered to SWOG leadership from 12.14.2021 to 01.13.2022. Questions were divided into 4 categories including: general beliefs regarding DEI, SWOG’s current status regarding DEI efforts, perception of SWOG’s values and readiness in executing DEI. Twenty questions were asked and answers were recorded using a 5-point Likert scale. Results: A total of 53% (N=47/88) respondents completed the survey (Table 1). The majority of SWOG leadership strongly agree that diversity is an asset (68%) and that they have a role to champion DEI (72%). Less than a quarter of SWOG leadership strongly agree that there are sufficient opportunities for committee members to provide DEI input across the clinical trial life cycle (21%). When evaluating SWOGs current role in DEI efforts, 64% of respondents had a neutral or negative response for each of the 4 questions. When evaluating respondents’ perception of SWOG values regarding DEI, 64% of respondents had a positive or very positive response on average for each of the 6 questions. When evaluating SWOG’s readiness to promote DEI, 57% of respondents had a positive or very positive response for each question. Some of the barriers experienced include technological issues with construction and delivery of the survey to protected email addresses as well as lack of dedicated staff at SWOG to assist. Conclusions: This survey provides insight into SWOG leader’s beliefs and knowledge regarding DEI as well as their perception of SWOG’s current efforts and ability to promote DEI in clinical trials. While respondents tended to value DEI positively personally and through SWOG, their perception of SWOG’s role in promoting DEI was neutral or negative. Perception of SWOGs readiness to promote DEI was positive to a lesser degree. These findings emphasize the importance of capturing baseline beliefs to promote DEI efforts with clinical trial leadership. [Table: see text]

  • Self‐reported experiences of discrimination and incident dementia

    by Michael P. Bancks, Goldie S. Byrd, Allison Caban‐Holt, Annette L. Fitzpatrick, Sarah N. Forrester, Kathleen M. Hayden, Susan R. Heckbert, Kiarri N. Kershaw, Stephen R. Rapp, Bonnie C. Sachs, et al.

    Introduction: Discrimination negatively impacts health and may contribute to racial/ethnic disparities in dementia risk.Methods: Experiences of lifetime and everyday discrimination were assessed among 6509 Multi‐Ethnic Study of Atherosclerosis (MESA) participants. We assessed the association of discrimination with incidence of dementia including adjustment for important risk factors, cohort attrition, and we assessed for effect modification by race/ethnicity.Results: Prevalence of any lifetime discrimination in MESA was 42%, highest among Black adults (72%). Over a median 15.7 years of follow‐up, there were 466 incident cases of dementia. Lifetime discrimination, but not everyday discrimination, was associated with incident dementia (Wald p = 0.03). Individuals reporting lifetime discrimination in ≥2 domains (compared to none) had greater risk for dementia (hazard ratio: 1.40; 95%: 1.08, 1.82) after adjustment for sociodemographic, clinical, and behavioral risk factors. Associations did not differ by race/ethnicity.Conclusions: These findings demonstrate an association of greater experiences of lifetime discrimination with incident dementia.


  • Open Access

    Identifying dementia in Down syndrome with the Severe Impairment Battery, Brief Praxis Test and Dementia Scale for People with Learning Disabilities

    by E. R. Wallace, J. P. Harp, K. L. Van Pelt, L. M. Koehl, A. M. Caban‐Holt, A. J. Anderson‐Mooney, G. A. Jicha, D. D. Lightner, W. C. Robertson, E. Head, et al.

    Background: Individuals with Down syndrome (DS) are at high risk for dementia, specifically Alzheimer's disease. However, many measures regularly used for the detection of dementia in the general population are not suitable for individuals with DS due in part to floor effects. Some measures, including the Severe Impairment Battery (SIB), Brief Praxis Test (BPT) and Dementia Scale for People with Learning Disabilities (DLD), have been used in clinical trials and other research with this population. Validity research is limited, particularly regarding the use of such tools for detection of prodromal dementia in the DS population. The current project presents baseline cross‐sectional SIB, BPT and DLD performance in order to characterise their predictive utility in discriminating normal cognition, possible dementia and probable dementia in adult DS.Method: Baseline SIB, BPT and DLD performances from 100 individuals (no dementia = 68, possible dementia = 16 & probable dementia = 16) were examined from a longitudinal cohort of aging individuals with DS. Receiver operating characteristic curves investigated the accuracy of these measures in relation to consensus dementia diagnoses, diagnoses which demonstrated high percent agreement with the examining neurologist's independent diagnostic impression.Results: The SIB and BPT exhibited fair discrimination ability for differentiating no/possible versus probable dementia [area under the curve (AUC) = 0.61 and 0.66, respectively]. The DLD exhibited good discrimination ability for differentiating no versus possible/probable dementia (AUC = 0.75) and further demonstrated better performance of the DLD Cognitive subscale compared with the DLD Social subscale (AUC = 0.77 and 0.67, respectively).Conclusions: Results suggest that the SIB, BPT and DLD are able to reasonably discriminate consensus dementia diagnoses in individuals with DS, supporting their continued use in the clinical assessment of dementia in DS. The general performance of these measures suggests that further work in the area of test development is needed to improve on the AUCs for dementia status discrimination in this unique population. At present, however, the current findings suggest that the DLD may be the best option for reliable identification of prodromal dementia in this population, reinforcing the importance of including informant behaviour ratings in assessment of cognition for adults with DS.